Longevity science has entered its execution era. What once sounded speculative now rests on clearer biology, richer human datasets, and maturing toolkits that are pushing longevity from buzzword to buildable therapeutic category. This session brings together leaders from industry and investment to define what durable aging and healthspan means in practice. This panel will explore how to prioritize key pathways, select effective therapeutic approaches, and identify biomarkers and functional readouts that truly matter in the longevity space. Attendees will leave with a framework for distinguishing hype from substance and for understanding what it will take to move longevity science from promising experiments to scalable, real-world medicines.